CellProthera inches closer to Phase III trial for heart attack cell therapy - Clinical Trials Arena
CellProthera's positive pre-IND meeting with FDA paves way for Phase III trial of ProtheraCytes, a cell therapy for myocardial infarction. The trial, with a two-year follow-up, aims to prevent subsequent heart diseases. The company plans to pursue RMAT designation for expedited development and review.
Highlighted Terms
Related News
CellProthera plans a pivotal phase III trial in the US and Europe for its ProtheraCytes cell therapy, following FDA alignment, to prevent heart diseases post-acute myocardial infarction (AMI).
CellProthera's positive pre-IND meeting with FDA paves way for Phase III trial of ProtheraCytes, a cell therapy for myocardial infarction. The trial, with a two-year follow-up, aims to prevent subsequent heart diseases. The company plans to pursue RMAT designation for expedited development and review.